ImmunityBio (IBRX) Projected to Post Quarterly Earnings on Tuesday

ImmunityBio (NASDAQ:IBRX - Get Free Report) will likely be posting its quarterly earnings results before the market opens on Tuesday, March 18th. Analysts expect ImmunityBio to post earnings of ($0.26) per share and revenue of $9.51 million for the quarter.

ImmunityBio (NASDAQ:IBRX - Get Free Report) last released its earnings results on Monday, March 3rd. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.26) by $0.11. The firm had revenue of $7.55 million during the quarter, compared to analysts' expectations of $8.74 million. On average, analysts expect ImmunityBio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

ImmunityBio Trading Down 1.6 %

Shares of NASDAQ IBRX traded down $0.05 during midday trading on Wednesday, reaching $2.77. 3,108,308 shares of the stock were exchanged, compared to its average volume of 5,973,090. The stock has a 50 day moving average price of $3.08 and a 200-day moving average price of $3.64. The company has a market capitalization of $2.36 billion, a P/E ratio of -3.01 and a beta of 0.82. ImmunityBio has a 52-week low of $2.28 and a 52-week high of $10.53.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on IBRX shares. HC Wainwright reiterated a "buy" rating and issued a $8.00 price target on shares of ImmunityBio in a report on Thursday, March 13th. D. Boral Capital reiterated a "buy" rating and issued a $30.00 target price on shares of ImmunityBio in a research note on Thursday, March 13th. Finally, BTIG Research assumed coverage on ImmunityBio in a research note on Friday, January 10th. They issued a "buy" rating and a $6.00 price target on the stock. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, ImmunityBio presently has a consensus rating of "Buy" and an average target price of $12.19.

Remove Ads

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.